28 May 2010
Melbourne, Australia; 28 May 2010: Australia's regenerative medicine company, Mesoblast Limited (ASX:MSB; USOTC:MBLTY), was featured yesterday by the ASX at its inaugural Small to Mid Caps Conference in Singapore.
Mesoblast was one of only two emerging market leaders in the healthcare sector that were showcased to around 150 targeted global investors. The conference featured only 15 companies, predominantly from the resources sector, with market capitalisations of up to A$1 billion.
Chief Executive, Professor Silviu Itescu, updated investors on Mesoblast's acquisition of its United States associate company, Angioblast Systems, its near term growth strategies and plans for early product revenues.
About Mesoblast
Mesoblast Limited (ASX:MSB;ADR:MBLTY) is a world leader in commercialising biologic products for the broad field of regenerative medicine. Mesoblast has the worldwide exclusive rights for a series of patents and technologies developed over more than 10 years relating to the identification, extraction, culture and uses of adult Mesenchymal Precursor Cells (MPCs).
For further information, please contact:
Julie Meldrum
Corporate Communications Director
T: + 61 (03) 9639 6036
E: julie.meldrum@mesoblast.com
W: www.mesoblast.com
| © Copyright 1996-2019 irasia.com Ltd. All rights reserved. |
|
DISCLAIMER: irasia.com Ltd makes no guarantee as to the accuracy or completeness of any
information provided on this website. Under no circumstances shall irasia.com Ltd be liable
for damages resulting from the use of the information provided on this website.
TRADEMARK & COPYRIGHT: All intellectual property rights subsisting in the contents of this website belong to irasia.com Ltd or have been lawfully licensed to irasia.com Ltd for use on this website. All rights under applicable laws are hereby reserved. Reproduction of this website in whole or in part without the express written permission of irasia.com Ltd is strictly prohibited. TERMS OF USE: Please read the Terms of Use governing the use of our website. |